| Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor) Implications for the Efficacy of Evolocumab A Thedrez, DJ Blom, S Ramin-Mangata, V Blanchard, M Croyal, ... Arteriosclerosis, thrombosis, and vascular biology 38 (3), 592-598, 2018 | 89 | 2018 |
| PCSK9 inhibition with alirocumab reduces lipoprotein (a) levels in nonhuman primates by lowering apolipoprotein (a) production rate M Croyal, TTT Tran, RH Blanchard, JC Le Bail, EF Villard, B Poirier, ... Clinical Science 132 (10), 1075-1083, 2018 | 45 | 2018 |
| VLDL (very-low-density lipoprotein)-Apo E (apolipoprotein E) may influence Lp (a)(lipoprotein [a]) synthesis or assembly M Croyal, V Blanchard, K Ouguerram, M Chétiveaux, L Cabioch, T Moyon, ... Arteriosclerosis, Thrombosis, and Vascular Biology 40 (3), 819-829, 2020 | 33 | 2020 |
| PCSK9: from biology to clinical applications V Blanchard, I Khantalin, S Ramin-Mangata, K Chémello, B Nativel, ... Pathology 51 (2), 177-183, 2019 | 33 | 2019 |
| Kinetics of plasma apolipoprotein E isoforms by LC-MS/MS: a pilot study V Blanchard, S Ramin-Mangata, S Billon-Crossouard, A Aguesse, ... Journal of Lipid Research 59 (5), 892-900, 2018 | 28 | 2018 |
| A high-throughput mass spectrometry-based assay for large-scale profiling of circulating human apolipoproteins [S] V Blanchard, D Garçon, C Jaunet, K Chemello, S Billon-Crossouard, ... Journal of Lipid Research 61 (7), 1128-1139, 2020 | 27 | 2020 |
| The size of apolipoprotein (a) is an independent determinant of the reduction in lipoprotein (a) induced by PCSK9 inhibitors V Blanchard, K Chemello, T Hollstein, CC Hong-Fong, F Schumann, ... Cardiovascular Research 118 (9), 2103-2111, 2022 | 25 | 2022 |
| Lipoprotein (a) cellular uptake ex vivo and hepatic capture in vivo is insensitive to PCSK9 inhibition with alirocumab K Chemello, S Beeské, TT Trang Tran, V Blanchard, EF Villard, B Poirier, ... Basic to Translational Science 5 (6), 549-557, 2020 | 25 | 2020 |
| Effects of proprotein convertase subtilisin kexin type 9 modulation in human pancreatic beta cells function S Ramin-Mangata, A Thedrez, B Nativel, N Diotel, V Blanchard, M Wargny, ... Atherosclerosis 326, 47-55, 2021 | 22 | 2021 |
| Circulating PCSK9 levels are not associated with the conversion to type 2 diabetes S Ramin-Mangata, M Wargny, M Pichelin, C Le May, A Thédrez, ... Atherosclerosis 293, 49-56, 2020 | 22 | 2020 |
| Smooth Muscle Cell—Macrophage Interactions Leading to Foam Cell Formation in Atherosclerosis: Location, Location, Location P Xiang, V Blanchard, GA Francis Frontiers in Physiology 13, 921597, 2022 | 18 | 2022 |
| Macrophages in atherosclerosis, first or second row players? E Checkouri, V Blanchard, O Meilhac Biomedicines 9 (9), 1214, 2021 | 14 | 2021 |
| Stable isotope kinetic study of ApoM (apolipoprotein M) M Croyal, S Billon-Crossouard, S Goulitquer, A Aguesse, L León, F Fall, ... Arteriosclerosis, Thrombosis, and Vascular Biology 38 (1), 255-261, 2018 | 13 | 2018 |
| Plasma apolipoprotein concentrations and incident diabetes in subjects with prediabetes M Croyal, M Wargny, K Chemello, C Chevalier, V Blanchard, ... Cardiovascular Diabetology 21 (1), 21, 2022 | 12 | 2022 |
| Plasma concentrations of lipoproteins and risk of lower-limb peripheral artery disease in people with type 2 diabetes: the SURDIAGENE study C Bertrand, PJ Saulnier, L Potier, M Croyal, V Blanchard, E Gand, ... Diabetologia 64, 668-680, 2021 | 12 | 2021 |
| Key aspects of PCSK9 inhibition beyond LDL lowering S Ramin-Mangata, V Blanchard, G Lambert Current Opinion in Lipidology 29 (6), 453-458, 2018 | 11 | 2018 |
| Genome-wide characterization of a highly penetrant form of hyperlipoprotein (a) emia associated with genetically elevated cardiovascular risk S Coassin, K Chemello, I Khantalin, L Forer, P Döttelmayer, S Schönherr, ... Circulation: Genomic and Precision Medicine 15 (2), e003489, 2022 | 8 | 2022 |
| Lysosomal acid lipase deficiency: A rare inherited dyslipidemia but potential ubiquitous factor in the development of atherosclerosis and fatty liver disease KJ Besler, V Blanchard, GA Francis Frontiers in Genetics 13, 1013266, 2022 | 6 | 2022 |
| Reduced lipoprotein (a) associated with the apolipoprotein E2 genotype confers cardiovascular protection in familial hypercholesterolemia V Blanchard, M Croyal, I Khantalin, S Ramin-Mangata, K Chemello, ... JACC: Basic to Translational Science 4 (3), 425-427, 2019 | 6 | 2019 |
| Homozygous FH patients with identical mutations variably express the LDL receptor: implications for the efficacy of evolocumab A Thedrez, DJ Blom, S Ramin-Mangata, V Blanchard, M Croyal, ... Arteriosclerosis, thrombosis, and vascular biology 38 (3), 592, 2018 | 5 | 2018 |
